Pacgen Life Science Corp  

(Public, CVE:PBS)   Watch this stock  
Find more results for CVE:pga
0.0300
Aug 31 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.05
Open     -
Vol / Avg. 0.00/22,796.00
Mkt cap 2.36M
P/E     -
Div/yield     -
EPS 0.00
Shares 47.22M
Beta 0.38
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2015
Net profit margin - 0.12%
Operating margin - -11.03%
EBITD margin - -10.24%
Return on average assets -14.47% 0.02%
Return on average equity -66.61% 0.10%
Employees 10 -
CDP Score - -

Address

Suite 1500, 701 West Georgia Street
VANCOUVER, BC V7Y 1C6
Canada
+1-604-4364388 (Phone)
+1-604-4364380 (Fax)

Website links

Description

Pacgen Life Science Corporation (Pacgen) is a Canada-based life science technology company. The Company is focused on the commercialization of biomedical products and services. The Company has a license to develop and commercialize a novel antifungal called PAC-113. The Company's PAC-113 is a 12 amino-acid antimicrobial peptide. The Company, through General Biologicals Corporation (GBC), offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan, including cosmetic skin-care products, oral hygiene products and intimate hygiene products. The Company's PAC-113, which is an anti-fungal for the treatment of oral Candidiasis infections, completed a Phase IIb clinical program. Its products include Fit X1 Series, Electronic Pipettes and A+ Pipette Controller. Its Fit X1 401 is an automated pipetting system. Pacgen's A+ Pipette Controller is an electronic pipette controller for use with graduated and volumetric glass and plastic pipettes.

Officers and directors

Chung-Yu Wang Chairman of the Board, Interim President and Chief Executive Officer
Christina Yip Chief Financial Officer, Corporate Secretary
Telvin Ju Ph.D. Lead Independent Director
Jeng-Horng Her Ph.D. Independent Director
Min-Chih Hsuan Independent Director
Age: 60
Frederick Huang Independent Director